India's March Towards Self-Reliance in Med-Tech

The Lift Line

Reducing import dependence in syringes and stents is not the same achievement as building India’s first domestically engineered surgical robot.

Why This Editorial Matters for Your Exam

Economy answers on manufacturing self-reliance tend to cite the PLI scheme by name and stop there, as if naming the scheme were evidence of its success. This editorial requires distinguishing between import-substitution progress that is real and measurable (simpler device categories) and a much larger, unproven claim (leadership in advanced med-tech), a distinction examiners specifically reward.

GS Paper 3: Indian economy and issues relating to planning, mobilisation of resources, growth, development and employment; infrastructure; science and technology, indigenisation of technology and developing new technology.

Background and Context

The op-ed comes from JP Nadda, Union Minister of Health and Family Welfare, published around the “Atmanirbhar MedTech: Accelerating India’s Journey towards Viksit Bharat” conference organised by the Department of Pharmaceuticals and FICCI in New Delhi on 7 to 8 August 2026.

India’s medical device sector has long been described as import-heavy, with import dependence commonly cited at 70 to 80 percent across several device categories, a legacy of limited domestic manufacturing and testing infrastructure relative to established manufacturing economies. The government’s response has centred on three instruments: the PLI scheme (manufacturing incentives), the Medical Device Parks scheme (common infrastructure), and the PRIP scheme (research and innovation support), each targeting a different part of the capacity-building problem.

The Analysis

1. The import-dependence baseline is real and the improvement is measurable, not merely claimed. A reported rise in domestic production’s share of domestic requirement from roughly 10 percent to 30 percent over five years is a specific, checkable trend, distinct from the more sweeping claim that India is positioned to lead in advanced med-tech.

2. The PLI scheme’s design targets manufacturing scale, not innovation. A 5 percent incentive on incremental sales rewards volume of domestic production; it does not by itself fund the engineering and regulatory-testing capability that advanced device categories require, which is a separate gap the PRIP scheme is meant to address.

3. The Medical Device Parks scheme’s reach is real but narrow. Final approval to four states, out of proposals from sixteen, means the common-infrastructure benefit is concentrated rather than national, a fact the piece’s framing of broad-based self-reliance elides.

4. The pharma-manufacturing analogy is the strongest genuine argument, and it has a real limit. Decades of experience manufacturing generic drugs at scale gives India regulatory and manufacturing-process expertise that many countries attempting similar import-substitution lack. But drug manufacturing and precision-device engineering are different capability sets; the analogy supports optimism about simpler devices more than it supports optimism about robotic surgery systems or advanced imaging equipment.

5. Market-size and ranking claims should be treated as indicative, not exact. India is commonly cited as Asia’s fourth-largest medical device market, but market-size estimates vary meaningfully across sources and methodologies, and a Mains answer should cite such rankings with that caveat rather than asserting them as a single settled figure.

6. Independent assessment of the PLI scheme’s actual performance is thin in the public domain. Most available data on scheme utilisation and impact comes from government sources; a more complete assessment would draw on independent industry or think-tank evaluation, which is not easy to find, a gap worth naming rather than assuming resolved in the scheme’s favour.

Data and Institutions Vault

Prelims-grade facts:

• PLI Scheme for Medical Devices: launched March 2020, Department of Pharmaceuticals; outlay Rs 3,420 crore (2020-21 to 2027-28); incentive 5% of incremental sales for 5 years
• Medical Device Parks scheme: 4 states given final approval, Uttar Pradesh, Tamil Nadu, Madhya Pradesh, Himachal Pradesh; each received Rs 100 crore; proposals received from 16 states/UTs
• PRIP scheme: Promotion of Research and Innovation in Pharma-MedTech
• Import dependence: commonly cited 70-80%; domestic share of domestic requirement reportedly grew from ~10% to ~30% over 5 years
• India commonly cited as Asia’s fourth-largest medical device market, after Japan, China, South Korea (ranking/market-size figures vary by source)
• Nodal ministry: Department of Pharmaceuticals, under the Ministry of Chemicals and Fertilizers (distinct from the Ministry of Health and Family Welfare, which Nadda also heads)

Watch the trap: do not conflate the Ministry of Health and Family Welfare with the Department of Pharmaceuticals; the PLI and Medical Device Parks schemes for devices sit administratively under Chemicals and Fertilizers, even though Nadda, as Health Minister, is a natural voice on the sector’s health-system implications.

The Debate

Argument FOR the government’s self-reliance record. India’s decades of pharmaceutical manufacturing experience, regulatory familiarity, process-engineering talent, supply-chain infrastructure, is a genuine and relatively rare foundation to build medical-device manufacturing on top of, and the reported shift in domestic production share from roughly 10 percent to 30 percent over five years is a real, checkable achievement, not merely a talking point.

Argument AGAINST reading this as evidence of advanced-tech leadership. The capability gap between manufacturing simpler, high-volume devices and engineering advanced categories, AI-enabled diagnostics, robotic surgery systems, precision imaging, is substantial, and a manufacturing-incentive scheme is not designed to close that specific gap. Independent, non-government assessment of the PLI scheme’s actual utilisation is thin, and market-ranking claims cited in support of the sector’s scale vary by source, both of which counsel caution before accepting the piece’s framing at face value.

Balanced verdict. The government’s case is strongest where it is most specific and checkable, import-dependence reduction in target manufacturing segments, and weakest where it is most aspirational, positioning for leadership in advanced med-tech categories. A sound Mains answer credits the real, measurable progress while treating the advanced-technology claim as a stated goal rather than a demonstrated outcome, and calls for the testing, certification and R&D infrastructure investment that the harder categories specifically require.

How to Think About This

The transferable pattern: when an industrial-policy op-ed cites a genuine foundational strength to support a much larger forward-looking claim, separate what the foundational strength actually demonstrates from what the forward claim requires, and check whether the instruments cited (incentive schemes, infrastructure parks) actually build the capability the forward claim depends on.

Manufacturing-incentive schemes are well suited to scaling production of goods where the underlying engineering and regulatory pathway is already established; they are poorly suited, on their own, to building genuinely new engineering or R&D capability, which requires sustained investment in talent, testing infrastructure and research funding rather than sales-linked incentives. A claim of “positioned to lead” in an advanced technology category should be checked against which of these two problems the cited instruments actually solve.

This same structure recurs in electronics manufacturing, where PLI-driven assembly-stage growth is sometimes read as evidence of design and semiconductor-fabrication capability it does not by itself establish; in defence indigenisation, where domestic assembly of imported-design platforms is sometimes conflated with genuine indigenous design capability; and in renewable energy manufacturing, where cell-assembly capacity growth is distinct from the raw-material and advanced-cell-technology capability a fuller self-reliance claim would require.

Diagram-in-Words

INDIA'S MED-TECH SELF-RELIANCE CLAIM

WHAT THE INSTRUMENTS ACTUALLY BUILD
PLI Scheme (Rs 3,420 cr, 2020-2028)
   -> incentivises manufacturing SCALE
   -> works well for: simpler, high-volume devices

Medical Device Parks (4 states approved)
   -> builds common manufacturing INFRASTRUCTURE
   -> works well for: manufacturing clusters, not R&D depth

PRIP Scheme
   -> supports RESEARCH AND INNOVATION
   -> the instrument actually aimed at advanced-tech capability

DEMONSTRATED PROGRESS
Import dependence: ~90% -> ~70% of domestic requirement
(domestic share grew ~10% -> ~30% over 5 years)
   |
   v
REAL, in simpler device categories

CLAIMED PROGRESS
"Positioned to lead in AI diagnostics, robotics"
   |
   v
REQUIRES: deep engineering + regulatory-testing infrastructure
+ sustained R&D investment
   |
   v
NOT YET DEMONSTRATED by manufacturing-incentive uptake alone

GAP: scaling production of known-design devices
     is not the same capability as engineering new,
     advanced-technology devices

Takeaway Box

Lift line for an answer:

India has proven it can manufacture more of what it used to import. It has not yet proven it can engineer what it has never made.

Prelims hooks: PLI Scheme for Medical Devices, launched March 2020, outlay Rs 3,420 crore (2020-21 to 2027-28), 5% incentive on incremental sales; Medical Device Parks: 4 states approved (UP, TN, MP, Himachal Pradesh), Rs 100 crore each, out of 16 state/UT proposals; PRIP scheme (research and innovation); nodal department: Department of Pharmaceuticals; import dependence commonly cited 70-80%, domestic share reportedly grew ~10% to ~30% in 5 years; India commonly cited as Asia’s 4th-largest medical device market.

Ethics and interview angle: when a minister’s own op-ed makes the government’s case for its own scheme’s success, what obligation does an aspirant, or a policy analyst, have to distinguish the government’s self-reported metrics from independently verified ones before accepting the claim?

PYQ linkage: UPSC has repeatedly examined Make in India, PLI schemes across sectors, and indigenisation of technology; this editorial supplies a sector-specific case, medical devices, to test whether manufacturing-incentive success in simpler categories generalises to advanced-technology leadership claims.

Probable question: “Import-substitution success in manufacturing scale does not automatically translate into leadership in advanced technology categories.” Examine with reference to India’s medical device sector and the instruments used to build it.

Sources: Hindustan Times, PIB, Department of Pharmaceuticals

Source: India's March Towards Self-Reliance in Med-Tech — Ujiyari.com | Free UPSC & State PCS Editorial Analysis